List of Excipients in Branded Drug CLOROTEKAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	CLOROTEKAL	chloroprocaine hydrochloride	0264-7055	HYDROCHLORIC ACID
B Braun Medical Inc	CLOROTEKAL	chloroprocaine hydrochloride	0264-7055	NITROGEN
B Braun Medical Inc	CLOROTEKAL	chloroprocaine hydrochloride	0264-7055	SODIUM CHLORIDE

Clorotekal Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Clorotekal is a preservative-free spinal anesthetic containing chloroprocaine hydrochloride, typically supplied as a 10 mg/mL injectable solution. Its commercial differentiation is based less on novel excipient chemistry than on rapid onset, short duration, preservative-free intrathecal use, ready-to-administer packaging, and hospital workflow efficiency. The core formulation appears difficult to protect with a strong composition-of-matter patent, creating opportunities in delivery systems, container closure, stability, manufacturing efficiency, and regional commercialization.

What is Clorotekal and what excipients does it contain?

Clorotekal contains chloroprocaine hydrochloride in an aqueous solution for injection. Public product information identifies the formulation excipients as sodium chloride, hydrochloric acid for pH adjustment, and water for injections.[1]

Component	Function	Strategic relevance
Chloroprocaine hydrochloride	Local anesthetic active ingredient	Established small-molecule API with limited modern compound-patent protection
Sodium chloride	Tonicity adjustment	Supports intrathecal tolerability and osmolality control
Hydrochloric acid	pH adjustment	Controls solution pH and chemical stability
Water for injections	Vehicle	Standard parenteral solvent
Preservative	None identified	Important for intrathecal safety and regulatory positioning

The formulation is intentionally simple. A preservative-free presentation reduces concerns associated with intrathecal administration, where antimicrobial preservatives such as benzyl alcohol or parabens are generally unsuitable.

Clorotekal is indicated for spinal anesthesia in adults for short surgical procedures, subject to the terms of the applicable national authorization.[1] The product is associated with Sintetica and related marketing-authorisation entities in European markets.

What formulation patents protect Clorotekal?

No broadly recognized composition-of-matter patent is likely to protect chloroprocaine hydrochloride itself. Chloroprocaine is an established anesthetic that predates modern pharmaceutical patent terms. The principal commercial protection opportunities therefore relate to the finished product rather than the active molecule.

Likely protection categories

Protection category	Relevance to Clorotekal	Expected strength
Chloroprocaine composition patent	Low	Very weak or expired
Preservative-free injectable solution	Moderate	Often difficult to patent broadly
Specific pH and osmolality range	Moderate	Potentially useful if linked to stability or safety data
Ampoule, vial, or prefilled syringe	Moderate	Usually narrow and design-around risk is high
Intrathecal administration method	Moderate	Dependent on claim scope and jurisdiction
Stability package	Moderate	Can support regulatory differentiation but is difficult to enforce alone
Manufacturing process	Moderate to high	Stronger if process yields a measurable purity or stability advantage
Combination with a spinal anesthesia workflow	Low to moderate	Commercially useful but potentially vulnerable to obviousness challenges
Device or administration system	Moderate to high	Can create practical switching costs

A formulation patent would have greater value if it claimed a defined combination of pH, osmolality, chloroprocaine concentration, impurity profile, container material, and sterilization conditions. A claim limited to "chloroprocaine hydrochloride, sodium chloride, hydrochloric acid, and water" would face substantial patentability and enforcement risks unless supported by an unexpected stability, safety, or manufacturing result.

How strong is the Clorotekal patent estate?

The patent estate is likely stronger as a product and regulatory package than as a traditional molecule patent estate.

Patent-strength assessment

Factor	Assessment
Active pharmaceutical ingredient	Weak exclusivity profile because chloroprocaine is an old molecule
Finished formulation	Moderate opportunity, but broad claims may be difficult to sustain
Intrathecal use	Potentially valuable where claims cover a defined clinical use or dosing protocol
Packaging	Useful for differentiation, but generally easy to design around
Manufacturing	Potentially meaningful if the process controls degradation products or sterility
Regulatory exclusivity	Market-specific and more important than patent protection in some countries
Generic substitution risk	High once a compliant injectable equivalent is approved
Biosimilar risk	Not applicable; Clorotekal is a small-molecule drug

The most defensible intellectual-property strategy would combine narrow formulation claims with process claims and proprietary data packages. A single excipient patent would not provide durable protection against a generic manufacturer using a different buffer, tonicity agent, container, or filling process.

When does Clorotekal lose exclusivity?

Clorotekal does not have one global exclusivity date. Exclusivity depends on the national marketing authorization, patent family, regulatory pathway, and any applicable data or market exclusivity.

Publicly available product information identifies the medicine and its approved composition but does not establish a single global patent expiration date.[1] The underlying chloroprocaine molecule is old, so commercial loss of exclusivity is more likely to arise from generic authorization, local procurement decisions, and regulatory substitution than from expiration of a current compound patent.

Exclusivity timeline

Event	Commercial effect
Original chloroprocaine approvals	Established the active ingredient and reduced long-term molecule-level exclusivity
Clorotekal national approvals	Created market-specific rights to sell the authorized product
Product-specific formulation or process filings	May provide limited, jurisdiction-specific protection
Generic injectable approval	Creates direct price and tender competition
Hospital tender substitution	Can reduce share before formal patent expiry
Loss of supply or authorization	Can create openings for alternative suppliers

For diligence purposes, the controlling documents are national patent registers, SPC databases, regulatory exclusivity records, and product-specific marketing authorizations. An Orange Book analysis alone is not sufficient because Clorotekal is not identified as a U.S. FDA-approved product under that brand.

What is the Orange Book status of Clorotekal?

Clorotekal does not appear to have a U.S. Orange Book listing under the Clorotekal brand. The Orange Book covers drug products approved by the FDA and does not provide a complete record of European or other national product rights.[2]

This has several consequences:

• There is no Clorotekal-specific U.S. Orange Book patent listing to support a Paragraph IV strategy.
• A U.S. challenger would need to assess the regulatory status of chloroprocaine hydrochloride products separately.
• European product rights cannot be inferred from the absence of a U.S. listing.
• A U.S. launch would require an FDA-approved application, which could involve an abbreviated new drug application, a 505(b)(2) application, or another applicable pathway depending on the reference product and formulation.

Are there Paragraph IV challenges against Clorotekal?

A conventional Paragraph IV challenge is not established for Clorotekal because the product is not identified as an FDA-approved brand with an Orange Book listing under that name.[2]

A U.S. generic strategy would instead focus on:

1. Identifying the applicable FDA reference-listed drug.
2. Confirming whether chloroprocaine hydrochloride injection has an approved reference product.
3. Comparing concentration, route, preservative status, container, and labeling.
4. Reviewing any active patents listed for the relevant U.S. reference product.
5. Assessing whether the product requires a 505(j) or 505(b)(2) pathway.

In Europe, the relevant challenges would involve national patent litigation, centralized or decentralized regulatory procedures where applicable, and procurement-level substitution. The absence of an Orange Book listing does not eliminate European patent risk.

What excipient strategy offers the best commercial opportunity?

The highest-value strategy is a preservative-free, ready-to-use formulation that reduces preparation steps without changing the clinical profile.

Strategy 1: Preserve the minimalist formulation

The existing excipient system has a low regulatory and manufacturing burden:

• Sodium chloride for tonicity.
• Hydrochloric acid for pH adjustment.
• Water for injections as the vehicle.
• No antimicrobial preservative.

This approach minimizes excipient qualification work and supports an efficient regulatory bridge to an established product.

Strategy 2: Optimize pH and osmolality

A differentiated formulation could claim a defined pH and osmolality range if data demonstrate:

• Lower degradation during shelf life.
• Reduced particulate formation.
• Improved compatibility with the container.
• Consistent intrathecal tolerability.
• Better performance after temperature excursions.

This strategy requires robust analytical evidence. A narrow pH claim without a demonstrated technical effect would be vulnerable to obviousness and enablement challenges.

Strategy 3: Develop ready-to-use presentations

Hospitals may value presentations that reduce preparation and medication-error risks:

Presentation	Commercial benefit	Main barrier
Single-dose ampoule	Low cost and familiar workflow	Breakage and withdrawal steps
Single-dose vial	Easier compatibility with existing systems	Requires needle withdrawal
Prefilled syringe	Reduces preparation time	Higher device and stability burden
Unit-dose blister or tray	Supports operating-room workflow	Packaging cost
Standardized anesthesia kit	Creates procurement convenience	Combination-product and logistics complexity

A prefilled syringe could provide the strongest commercial differentiation, but it would require extractables and leachables testing, device compatibility work, container-closure validation, and careful control of delivered volume.

Strategy 4: Use alternative tonicity agents only when justified

Potential alternatives to sodium chloride include dextrose or other parenteral tonicity agents. They could support a differentiated osmolality profile, but substitution introduces new development risks:

• Different chemical stability behavior.
• New impurity pathways.
• Changed density and fill-volume calculations.
• Different intrathecal safety evidence.
• More extensive bridging requirements.

For a generic or line-extension strategy, replacing sodium chloride is unlikely to be commercially attractive unless it solves a documented stability, compatibility, or administration problem.

What manufacturing and IP barriers affect generic entry?

The active ingredient is not the only barrier. Sterile injectable development requires control of several technical variables:

• API purity and related substances.
• Hydrolysis and degradation products.
• Endotoxin levels.
• Sterility assurance.
• Particulate matter.
• pH drift during storage.
• Container-closure integrity.
• Adsorption to glass, polymer, or elastomer components.
• Fill-volume accuracy.
• Compatibility with terminal sterilization or aseptic processing.

A manufacturer with reliable sterile filling capacity may compete effectively even without a strong patent estate. The key barrier is operational execution, not molecule access.

A process patent could be commercially relevant if it protects a high-purity chloroprocaine hydrochloride process, controls a known degradation impurity, or enables terminal sterilization while maintaining specification. Process claims should be supported by comparative data against conventional synthesis or filling methods.

What regulatory opportunities exist for Clorotekal alternatives?

Clorotekal alternatives can pursue several commercial routes, depending on jurisdiction.

Generic injectable route

A conventional generic strategy is most attractive where the product can demonstrate pharmaceutical equivalence, comparable quality, and the required safety and efficacy bridge. The formulation should remain close to the reference product to reduce development complexity.

505(b)(2) route in the United States

A 505(b)(2) application could be relevant if the proposed product differs materially in:

• Delivery device.
• Concentration.
• Container.
• Dosing presentation.
• Ready-to-use configuration.
• Administration workflow.

The pathway would still require a defensible regulatory bridge to existing chloroprocaine evidence.

Hospital-use line extension

A manufacturer could target hospitals with:

• Ready-to-use syringes.
• Smaller or larger unit doses.
• Operating-room kits.
• Barcoded unit-dose packaging.
• Supply contracts with anesthesia groups.
• Regional presentations aligned with national labeling requirements.

The commercial case depends on procurement savings and reduced preparation time rather than a premium based solely on excipient novelty.

Which companies are positioned to challenge or compete with Clorotekal?

The competitive field includes three groups:

1. Established injectable-anesthetic manufacturers with sterile filling capacity.
2. Generic companies holding or developing chloroprocaine products.
3. Contract development and manufacturing organizations able to manufacture preservative-free intrathecal injections.

The most credible competitors are companies with:

• Existing hospital injectable portfolios.
• Regulatory experience with spinal or epidural products.
• Reliable glass or polymer container supply.
• Aseptic fill-finish capacity.
• European and U.S. regulatory infrastructure.
• Hospital tender access.

The primary competitive threat is likely to come from a lower-cost equivalent rather than a product with a substantially different excipient system.

What licensing deals could create value?

Licensing opportunities are strongest in four areas:

Licensing asset	Potential buyer	Value driver
Regional marketing rights	Specialty pharmaceutical company	Immediate commercial access
Ready-to-use syringe platform	Injectable manufacturer	Workflow differentiation
Sterile manufacturing process	CDMO or generic company	Lower cost and reliable supply
Hospital anesthesia kit	Medical-device or hospital supplier	Bundled procurement and switching costs

A regional license should address formulation ownership, manufacturing responsibility, pharmacovigilance, regulatory maintenance, supply commitments, tender participation, and rights to future presentations.

A device-linked license can be more defensible than a simple formulation license if it includes validated container compatibility, filling parameters, and human-factors data.

What revenue exposure and launch scenarios exist?

Clorotekal revenue exposure is concentrated in hospital and ambulatory surgical settings. Demand depends on procedure volume, anesthesia practice, reimbursement, availability of competing local anesthetics, and hospital tender cycles.

Generic launch scenarios

Scenario	Timing	Expected commercial effect
Direct injectable equivalent	After regulatory approval and patent clearance	Rapid price pressure in tenders
Lower-cost regional product	Market-specific	Share gains where procurement is price-led
Prefilled syringe	Later launch	Premium potential through workflow savings
Hospital anesthesia kit	Medium-term	Greater account stickiness but higher operational complexity
Supply-constrained entry	Opportunistic	Temporary pricing power during shortages

The most exposed revenue is tender-driven business where hospitals can substitute an equivalent product. A differentiated presentation may protect net price, but only if procurement teams quantify labor savings, error reduction, inventory control, or wastage reduction.

How does Clorotekal compare with other local anesthetics?

Attribute	Clorotekal	Bupivacaine spinal products	Lidocaine spinal products
Active ingredient	Chloroprocaine hydrochloride	Bupivacaine hydrochloride	Lidocaine hydrochloride
Typical clinical positioning	Short spinal procedures	Longer-duration anesthesia	Short procedures, with historical safety considerations
Preservative-free requirement	Important for intrathecal use	Important for intrathecal use	Important for intrathecal use
Excipient complexity	Low	Low to moderate	Low
Generic substitution risk	High after approval	High	High
Differentiation opportunity	Speed, recovery profile, presentation	Duration and established use	Cost and familiarity
Patent opportunity	Formulation, device, process	Formulation, device, process	Limited molecule-level opportunity

Clorotekal’s commercial position depends on the clinical value of short duration and recovery speed. Excipient innovation alone is unlikely to displace established alternatives.

Key Takeaways

• Clorotekal is a preservative-free chloroprocaine hydrochloride spinal anesthetic.
• Its disclosed excipients are sodium chloride, hydrochloric acid, and water for injections.[1]
• The underlying molecule is old, making strong composition-of-matter protection unlikely.
• The most credible IP opportunities involve defined pH and osmolality ranges, stability, sterile manufacturing, packaging, and delivery devices.
• Clorotekal has no established U.S. Orange Book listing under that brand.[2]
• A Paragraph IV strategy would require identification of the relevant U.S. reference-listed drug rather than reliance on the Clorotekal name.
• The best commercial opportunity is a preservative-free, ready-to-use presentation that reduces operating-room preparation and procurement friction.
• Biosimilar risk is not relevant because chloroprocaine is a small-molecule drug.
• Generic entry risk is high once a compliant injectable equivalent reaches a target market.
• Manufacturing capability, sterile supply reliability, and hospital tender access are likely to matter more than broad excipient patent protection.

FAQs

Can sodium chloride be replaced in a Clorotekal generic formulation?

Yes, but substitution would increase formulation, safety, stability, and regulatory work. Sodium chloride is the most straightforward tonicity agent for a close generic formulation.

Could a prefilled Clorotekal syringe receive patent protection?

Potentially. Patentability would depend on the specific syringe, closure, formulation stability, delivered-volume accuracy, compatibility data, or administration workflow. A generic claim to a chloroprocaine prefilled syringe would face significant prior-art risk.

Is chloroprocaine hydrochloride suitable for a 505(b)(2) product?

It may be, depending on the proposed formulation, presentation, reference product, and FDA regulatory history. A materially different device or ready-to-use configuration could support a 505(b)(2) rationale, but the pathway would require a product-specific assessment.

What is the main technical risk in developing a Clorotekal alternative?

The principal risk is sterile injectable quality: impurity control, particulate matter, container compatibility, sterility assurance, and stability through shelf life. Excipient selection is relatively simple compared with fill-finish execution.

Can hospital kits create stronger commercial protection than an excipient patent?

Yes. A hospital kit can create procurement and workflow advantages, but its protection is commercial rather than absolute. Competitors may reproduce the kit structure unless the device, packaging, process, or workflow is separately protected.

References

1. Electronic Medicines Compendium. (n.d.). Clorotekal 10 mg/mL solution for injection: Summary of product characteristics.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.